Premium
The effect of haemopoietic growth factors on the cell cycle of AML progenitors and their sensitivity to cytosine arabinoside in vitro
Author(s) -
SMITH M. A.,
SINGER C. R. J.,
PALLISTER C. J.,
SMITH J. G.
Publication year - 1995
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.1995.tb05194.x
Subject(s) - cytosine , in vitro , progenitor cell , cancer research , sensitivity (control systems) , biology , medicine , stem cell , microbiology and biotechnology , genetics , dna , electronic engineering , engineering
Summary. This study examines the effect of pretreatment in liquid culture of acute myeloid leukaemic (AML) progenitors with recombinant human IL‐3 or G and GM‐CSF. Prior to and following cytokine priming, the sensitivity of cells to cytosine arabinoside (Ara‐C) at concentrations ranging from 10 −12 to 1(T −4 M was assessed in clonogenic culture. In addition, the initial percentage of AML cells in S phase was assessed and their subsequent kinetic response to cytokine treatment evaluated by FACScan analysis. Light‐density marrow cells (LDMCs) from 19 AML patients were initially T‐cell and monocyte depleted in order to remove potential sources of endogenous cytokine production prior to in vitro investigation. LDMCs were incubated in liquid phase for 7 d in a chemically defined complete medium with or without cytokines. Clonogenic data from fresh AML LDMCs not pretreated with growth factors demonstrated a heterogenous response to Ara‐C. In only 4/15 marrows tested clonogenically was there any improvement in sensitivity to Ara‐C following cytokine priming. S‐phase data on all 19 marrows were similarly variable either before or after cytokine preincubation. There was no discernible correlation between clonogenic and kinetic data, nor could any relationship be established between in vitro findings and the FAB subtypes of patients or clinical outcomes. In summary, it would appear that the cell‐cycle status of AML cells is likely to be only one of many contributory factors governing the sensitivity of AML progenitors to Ara‐C. The clinical response of AML patients to cytokine therapy in association with cell‐cycle‐specific cytotoxic agents may therefore be variable and unpredictable.